Sylvia L Asa

List of Publications by Year
in descending order

560 papers	38,175 citations	90 h-index	172 g-index
620 all docs	620 docs citations	620 times ranked	25165 citing authors

#	Article	IF	Citations
1	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	13.5	2,318
2	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	2.4	1,738
3	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	3.4	1,192
4	The prevalence of pituitary adenomas. Cancer, 2004, 101, 613-619.	2.0	1,126
5	The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surgery, 2016, 151, 959.	2.2	840
6	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 2006, 6, 292-306.	12.8	797
7	Induction of intestinal epithelial proliferation by glucagon-like peptide 2.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7911-7916.	3.3	777
8	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	2.9	739
9	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2012, 22, 1104-1139.	2.4	717
10	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
11	Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14938-14943.	3.3	504
12	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	7.7	482
13	Observer Variation in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2004, 28, 1336-1340.	2.1	456
14	Pituitary Lactotroph Hyperplasia and Chronic Hyperprolactinemia in Dopamine D2 Receptor-Deficient Mice. Neuron, 1997, 19, 103-113.	3.8	398
15	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	5.2	388
16	EWSR1â€ATF1 fusion is a novel and consistent finding in hyalinizing clearâ€cell carcinoma of salivary gland. Genes Chromosomes and Cancer, 2011, 50, 559-570.	1.5	339
17	Pulmonary pathology of severe acute respiratory syndrome in Toronto. Modern Pathology, 2005, 18, 1-10.	2.9	331
18	The pathogenesis of pituitary tumours. Nature Reviews Cancer, 2002, 2, 836-849.	12.8	327

#	Article	IF	Citations
19	Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma. Modern Pathology, 2001, 14, 338-342.	2.9	298
20	The Cytogenesis and Pathogenesis of Pituitary Adenomas*. Endocrine Reviews, 1998, 19, 798-827.	8.9	285
21	Interobserver and Intraobserver Variation Among Experts in the Diagnosis of Thyroid Follicular Lesions With Borderline Nuclear Features of Papillary Carcinoma. American Journal of Clinical Pathology, 2008, 130, 736-744.	0.4	280
22	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics, 2013, 45, 1483-1486.	9.4	275
23	A Case for Hypothalamic Acromegaly: A Clinicopathological Study of Six Patients with Hypothalamic Gangliocytomas Producing Growth Hormone-Releasing Factor*. Journal of Clinical Endocrinology and Metabolism, 1984, 58, 796-803.	1.8	271
24	Growth Hormone-Releasing Hormone-Producing Tumors: Clinical, Biochemical, and Morphological Manifestations*. Endocrine Reviews, 1988, 9, 357-373.	8.9	265
25	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer, 2017, 24, C5-C8.	1.6	262
26	Distinct MultipleRET/PTC Gene Rearrangements in Multifocal Papillary Thyroid Neoplasia¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4116-4122.	1.8	242
27	Immunomodulation by bromocriptine. Immunopharmacology, 1983, 6, 231-243.	2.0	236
28	Lymphocytic Hypophysitis of Pregnancy Resulting in Hypopituitarism: A Distinct Clinicopathologic Entity. Annals of Internal Medicine, 1981, 95, 166.	2.0	232
29	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology, 2022, 33, 115-154.	5.2	227
30	The Pathogenesis of Pituitary Tumors. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 97-126.	9.6	225
31	Cystic Lesions of the Pituitary: Clinicopathological Features Distinguishing Craniopharyngioma, Rathkeâ€™s Cleft Cyst, and Arachnoid Cyst. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3972-3982.	1.8	221
32	Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCCâ€“PGL syndromes: a clinicopathological and molecular analysis. European Journal of Endocrinology, 2014, 170, 1-12.	1.9	219
33	RET Oncogene Activation in Papillary Thyroid Carcinoma. Advances in Anatomic Pathology, 2001, 8, 345-354.	2.4	205
34	Thyroid calcification and its association with thyroid carcinoma. Head and Neck, 2002, 24, 651-655.	0.9	204
35	The Demise of Follicular Carcinoma of the Thyroid Gland. Thyroid, 1994, 4, 233-236.	2.4	192
36	The Spectrum and Significance of Primary Hypophysitis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1048-1053.	1.8	182

#	Article	IF	Citations
37	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
38	Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Modern Pathology, 2011, 24, 1545-1552.	2.9	178
39	Overview of the 2022 WHO Classification of Pituitary Tumors. Endocrine Pathology, 2022, 33, 6-26.	5.2	174
40	Analysis of ret/PTC Gene Rearrangements Refines the Fine Needle Aspiration Diagnosis of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2187-2190.	1.8	169
41	The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocrine Pathology, 2015, 26, 349-355.	5.2	167
42	The Implication of Somatotroph Adenoma Phenotype to Somatostatin Analog Responsiveness in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6290-6295.	1.8	165
43	Gonadotropin Secretion in Vitro by Human Pituitary Null Cell Adenomas and Oncocytomas**. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 1011-1019.	1.8	162
44	â€œWarthin-like Tumorâ€•of the Thyroid. American Journal of Surgical Pathology, 1995, 19, 810-814.	2.1	162
45	Pituitary Lactotroph Adenomas Develop after Prolonged Lactotroph Hyperplasia in Dopamine D2 Receptor-Deficient Mice1. Endocrinology, 1999, 140, 5348-5355.	1.4	159
46	Parathyroid Hormone-Like Peptide in Normal and Neoplastic Human Endocrine Tissues*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1112-1118.	1.8	157
47	Targeted expression of a human pituitary tumorâ€“derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation, 2002, 109, 69-78.	3.9	155
48	Hyalinizing Trabecular Tumor of the Thyroid: A Variant of Papillary Carcinoma Proved By Molecular Genetics. American Journal of Surgical Pathology, 2000, 24, 1622-1626.	2.1	153
49	Fatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by Coronavirus. Journal of Infectious Diseases, 2005, 191, 193-197.	1.9	153
50	Spindle Cell Oncocytomas and Granular Cell Tumors of the Pituitary Are Variants of Pituicytoma. American Journal of Surgical Pathology, 2013, 37, 1694-1699.	2.1	151
51	Familial Adenomatous Polyposis-Associated Thyroid Cancer. American Journal of Pathology, 1999, 154, 127-135.	1.9	150
52	Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5-9.	1.8	150
53	Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. Journal of Endocrinology, 2000, 167, 417-428.	1.2	149
54	Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Clinical Cancer Research, 2016, 22, 250-258.	3.2	149

#	Article	IF	Citations
55	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Human Pathology, 2009, 40, 1070-1081.	1.1	147
56	Growth Enhancement in Suppressor of Cytokine Signaling 2 (SOCS-2)-Deficient Mice Is Dependent on Signal Transducer and Activator of Transcription 5b (STAT5b). Molecular Endocrinology, 2002, 16, 1394-1406.	3.7	145
57	Cushing's Disease Associated with an Intrasellar Gangliocytoma Producing Corticotrophin-Releasing Factor. Annals of Internal Medicine, 1984, 101, 789.	2.0	141
58	OVARIAN TRANSFORMING GROWTH FACTOR-Î± GENE EXPRESSION: IMMUNOHISTOCHEMICAL LOCALIZATION TO THE THECAINTERSTITIAL CELLS. Endocrinology, 1987, 121, 1577-1579.	1.4	128
59	The Melanoma-Associated Antigen A3 Mediates Fibronectin-Controlled Cancer Progression and Metastasis. Cancer Research, 2008, 68, 8104-8112.	0.4	127
60	Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1814-1818.	1.8	126
61	Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in Nonfunctioning Pituitary Adenomas: A High Throughput TMA, Immunohistochemical Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1745-1751.	1.8	123
62	Biomarkers of aggressive pituitary adenomas. Journal of Molecular Endocrinology, 2012, 49, R69-R78.	1.1	123
63	The Cloning and Chromosomal Mapping of Two Novel Human Opioid-Somatostatin-like Receptor Genes, GPR7 and GPR8, Expressed in Discrete Areas of the Brain. Genomics, 1995, 28, 84-91.	1.3	122
64	The 2004 World Health Organization classification of pituitary tumors: What is new?. Acta Neuropathologica, 2006, 111, 1-7.	3.9	121
65	Myostatin Is a Skeletal Muscle Target of Growth Hormone Anabolic Action. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5490-5496.	1.8	120
66	Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Modern Pathology, 2009, 22, 431-441.	2.9	120
67	Clinicopathological Correlations in Pituitary Adenomas. Brain Pathology, 2012, 22, 443-453.	2.1	120
68	Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Modern Pathology, 2018, 31, 900-909.	2.9	120
69	The influence of pituitary hormones on adjuvant arthritis. Arthritis and Rheumatism, 1984, 27, 682-688.	6.7	119
70	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1160-1166.	1.8	116
71	Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma. Endocrinology, 2005, 146, 1145-1153.	1.4	115
72	Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocrine Pathology, 2022, 33, 90-114.	5.2	115

#	Article	IF	Citations
73	Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Modern Pathology, 2016, 29, 131-142.	2.9	114
74	Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?. World Journal of Surgery, 2018, 42, 321-326.	0.8	114
75	Clonality of Thyroid Nodules in Sporadic Goiter. Diagnostic Molecular Pathology, 1995, 4, 113-121.	2.1	113
76	Application of Immunohistochemistry to Thyroid Neoplasms. Archives of Pathology and Laboratory Medicine, 2008, 132, 359-372.	1.2	113
77	Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling1. Endocrinology, 2000, 141, 752-762.	1.4	111
78	Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 878-882.	1.8	111
79	Human Fetal Adenohypophysis. Neuroendocrinology, 1988, 48, 423-431.	1.2	109
80	Essential Requirement forPax6 in Control of Enteroendocrine Proglucagon Gene Transcription. Molecular Endocrinology, 1999, 13, 1474-1486.	3.7	105
81	Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer, 2006, 107, 1786-1792.	2.0	105
82	The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. Journal of Clinical Medicine, 2018, 7, 280.	1.0	104
83	Prevalence of Activating ras Mutations in Morphologically Characterized Thyroid Nodules. Thyroid, 1996, 6, 409-416.	2.4	103
84	Expression of Growth Factors and Growth Factor Receptors in Normal and Tumorous Human Thyroid Tissues. Thyroid, 1995, 5, 67-73.	2.4	102
85	Adenohypophysial Changes in Mice Transgenic for Human Growth Hormone-Releasing Factor: A Histological, Immunocytochemical, and Electron Microscopic Investigation*. Endocrinology, 1989, 125, 2710-2718.	1.4	101
86	Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. Journal of Clinical Investigation, 2002, 110, 973-981.	3.9	95
87	Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 656-662.	1.8	95
88	Human Fetal Adenohypophysis. Neuroendocrinology, 1986, 43, 308-316.	1.2	94
89	Measures of Submaximal Aerobic Performance Evaluate and Predict Functional Response to Growth Hormone (GH) Treatment in GH-Deficient Adults1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4570-4577.	1.8	94
90	Controversies in Thyroid Pathology: Thyroid Capsule Invasion and Extrathyroidal Extension. Annals of Surgical Oncology, 2010, 17, 386-391.	0.7	94

#	Article	IF	Citations
91	Intratumoral Lymphatics and Lymph Node Metastases in Papillary Thyroid Carcinoma. JAMA Otolaryngology, 2003, 129, 716.	1.5	93
92	Î±-Transforming Growth Factor in the Bovine Anterior Pituitary Gland: Secretion by Dispersed Cells and Immunohistochemical Localization*. Endocrinology, 1987, 121, 1412-1416.	1.4	92
93	Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Modern Pathology, 2007, 20, 1269-1277.	2.9	91
94	The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2165-2170.	1.8	89
95	Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 878-882.	1.8	89
96	Epression of the Apoptosis-Inducing FAS Ligand (FASL) in Human First and Third Trimester Placenta and Choriocarcinoma Cells. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3173-3175.	1.8	88
97	Oncogene profile of papillary thyroid carcinoma. Surgery, 1999, 125, 46-52.	1.0	86
98	Cyclin D1 Protein Expression Predicts Metastatic Behavior in Thyroid Papillary Microcarcinomas But Is Not Associated with Gene Amplification. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1810-1813.	1.8	86
99	Pituitary Tumor-Derived Fibroblast Growth Factor Receptor 4 Isoform Disrupts Neural Cell-Adhesion Molecule/N-Cadherin Signaling to Diminish Cell Adhesiveness: A Mechanism Underlying Pituitary Neoplasia. Molecular Endocrinology, 2004, 18, 2543-2552.	3.7	86
100	Mechanisms of Disease: the pathogenesis of pituitary tumors. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 220-230.	2.9	85
101	Completion Thyroidectomy Versus Total Thyroidectomy: Is There a Difference in Complication Rates? An Analysis of 350 Patients. Journal of the American College of Surgeons, 2007, 205, 602-607.	0.2	85
102	Precursor lesions of endocrine system neoplasms. Pathology, 2013, 45, 316-330.	0.3	84
103	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. British Journal of Cancer, 2019, 120, 1113-1119.	2.9	83
104	Practical Pituitary Pathology: What Does the Pathologist Need to Know?. Archives of Pathology and Laboratory Medicine, 2008, 132, 1231-1240.	1.2	82
105	Hypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegaly. Acta Neuropathologica, 1980, 52, 231-234.	3.9	81
106	Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways. American Journal of Pathology, 2002, 160, 511-519.	1.9	80
107	Gangliocytomas of the sellar region â€" a review. Experimental and Clinical Endocrinology and Diabetes, 1995, 103, 129-149.	0.6	78
108	Ikaros Isoforms in Human Pituitary Tumors. American Journal of Pathology, 2003, 163, 1177-1184.	1.9	78

#	Article	IF	Citations
109	Concurrent Medullary and Papillary Carcinomas of Thyroid with Lymph Node Metastases. American Journal of Surgical Pathology, 1996, 20, 245-250.	2.1	78
110	Immunohistological Localization of Growth Hormone-Releasing Hormone in Human Tumors*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 423-427.	1.8	77
111	Gigantism Due to Pituitary Mammosomatotroph Hyperplasia. New England Journal of Medicine, 1990, 323, 322-327.	13.9	77
112	Analysis of Hormone Secretion by Clinically Nonfunctioning Human Pituitary Adenomas Using the Reverse Hemolytic Plaque Assay*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 73-80.	1.8	76
113	Islet Cell and Extrapancreatic Expression of the LIM Domain Homeobox Geneisl-1. Molecular Endocrinology, 1991, 5, 1633-1641.	3.7	76
114	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	2.1	75
115	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treatment Reviews, 2016, 47, 32-45.	3.4	74
116	Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathology, 2003, 14, 183-191.	5.2	73
117	Utilization of ancillary studies in thyroid fine needle aspirates: A synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagnostic Cytopathology, 2008, 36, 438-441.	0.5	73
118	Pituitary-Specific Knockout of the Carney Complex Gene Prkar1a Leads to Pituitary Tumorigenesis. Molecular Endocrinology, 2008, 22, 380-387.	3.7	73
119	The pars tuberalis of the human pituitary. Virchows Archiv A, Pathological Anatomy and Histology, 1982, 399, 49-59.	1.3	72
120	Lipid Degeneration in Pheochromocytomas Mimicking Adrenal Cortical Tumors. American Journal of Surgical Pathology, 1987, 11, 480-486.	2.1	72
121	Limbic Seizures Alter Reproductive Function in the Female Rat. Epilepsia, 1999, 40, 1370-1377.	2.6	72
122	Cytoplasmic Expression of Fibroblast Growth Factor Receptor-4 in Human Pituitary Adenomas: Relation to Tumor Type, Size, Proliferation, and Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1904-1911.	1.8	72
123	Pancreatic endocrine tumors. Modern Pathology, 2011, 24, S66-S77.	2.9	72
124	Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia. Clinical Cancer Research, 2008, 14, 1984-1996.	3.2	70
125	Vasoactive intestinal peptide-containing nerves in Peyer's patches. Brain, Behavior, and Immunity, 1987, 1, 148-158.	2.0	69
126	Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia?. Life Sciences, 1995, 56, 1523-1527.	2.0	69

#	Article	IF	Citations
127	Pit-1 Binding Sites at the Somatotrope-specific DNase I Hypersensitive Sites I, II of the Human Growth Hormone Locus Control Region Are Essential for in Vivo hGH-N Gene Activation. Journal of Biological Chemistry, 1999, 274, 35725-35733.	1.6	68
128	Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells. American Journal of Pathology, 2007, 170, 1618-1628.	1.9	68
129	A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior. Clinical Cancer Research, 2011, 17, 2385-2394.	3.2	67
130	Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Research, 2003, 63, 3716-23.	0.4	67
131	Pituitary Hormones and Contact Sensitivity in Rats. Allergy: European Journal of Allergy and Clinical Immunology, 1983, 38, 325-330.	2.7	66
132	Loss of Membrane Localization and Aberrant Nuclear E-cadherin Expression Correlates With Invasion in Pancreatic Endocrine Tumors. American Journal of Surgical Pathology, 2008, 32, 413-419.	2.1	66
133	The Current Histologic Classification of Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 1-22.	1.2	66
134	Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression. Cancer Research, 2007, 67, 5461-5470.	0.4	65
135	Oncocytes, Oxyphils, HÃ¼rthle, and Askanazy Cells: Morphological and Molecular Features Of Oncocytic Thyroid Nodules. Endocrine Pathology, 2010, 21, 16-24.	5.2	65
136	Diagnosis and Pathologic Characteristics of Medullary Thyroid Carcinomaâ€"Review of Current Guidelines. Current Oncology, 2019, 26, 338-344.	0.9	65
137	Papillary Thyroid Carcinoma: An Overview. Archives of Pathology and Laboratory Medicine, 2006, 130, 1057-1062.	1.2	65
138	TheMEN-1Gene Is Rarely Down-Regulated in Pituitary Adenomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3210-3212.	1.8	64
139	A Growth Hormone Receptor Mutation Impairs Growth Hormone Autofeedback Signaling in Pituitary Tumors. Cancer Research, 2007, 67, 7505-7511.	0.4	64
140	Prognostic Features in Tall Cell Papillary Carcinoma and Insular Thyroid Carcinoma. Laryngoscope, 1997, 107, 254-259.	1.1	63
141	DNase I-hypersensitive sites I and II of the human growth hormone locus control region are a major developmental activator of somatotrope gene expression. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10655-10660.	3.3	62
142	Evidence for Growth Hormone (GH) Autoregulation in Pituitary Somatotrophs in GH Antagonist-Transgenic Mice and GH Receptor-Deficient Mice. American Journal of Pathology, 2000, 156, 1009-1015.	1.9	61
143	Severe Acute Respiratory Syndromeâ€"associated Coronavirus in Lung Tissue. Emerging Infectious Diseases, 2004, 10, 20-24.	2.0	61
144	The Predictive Value of CK19 and CD99 in Pancreatic Endocrine Tumors. American Journal of Surgical Pathology, 2006, 30, 1588-1594.	2.1	61

#	Article	IF	Citations
145	The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocrine-Related Cancer, 2014, 21, R331-R344.	1.6	61
146	Pituitary Mammosomatotroph Adenomas Develop in Old Mice Transgenic for Growth Hormone-Releasing Hormone. Experimental Biology and Medicine, 1990, 193, 232-235.	1.1	60
147	Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocrine Pathology, 1995, 6, 125-134.	5.2	60
148	CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene, 2007, 26, 2747-2758.	2.6	60
149	The Role of Immunohistochemical Markers in the Diagnosis of Follicular-Patterned Lesions of the Thyroid. Endocrine Pathology, 2005, 16, 295-310.	5.2	59
150	The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis. PLoS Genetics, 2011, 7, e1002400.	1.5	59
151	Clinical features of silent corticotroph adenomas. Acta Neurochirurgica, 2012, 154, 1493-1498.	0.9	59
152	Postnatal Ablation of POMC Neurons Induces an Obese Phenotype Characterized by Decreased Food Intake and Enhanced Anxiety-Like Behavior. Molecular Endocrinology, 2013, 27, 1091-1102.	3.7	59
153	Primary thyroid thymoma: A distinct clinicopathologic entity. Human Pathology, 1988, 19, 1463-1467.	1.1	58
154	Transforming growth factor-Î± in normal and neoplastic human endocrine tissues. Human Pathology, 1992, 23, 1360-1365.	1.1	58
155	Underexpression of p27/Kip in Thyroid Papillary Microcarcinomas With Gross Metastatic Disease. JAMA Otolaryngology, 2002, 128, 253.	1.5	58
156	Vitamin D3 Administration Induces Nuclear p27 Accumulation, Restores Differentiation, and Reduces Tumor Burden in a Mouse Model of Metastatic Follicular Thyroid Cancer. Endocrinology, 2004, 145, 5840-5846.	1.4	58
157	Carney Complex with Adrenal Cortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E202-E206.	1.8	57
158	Biomarkers of Parathyroid Carcinoma. Endocrine Pathology, 2012, 23, 221-231.	5.2	57
159	Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clinical Cancer Research, 2005, 11, 1336-41.	3.2	57
160	INTRASELLAR GANGLIOCYTOMA CONTAINING GASTRIN AND GROWTH HORMONEâ€RELEASING HORMONE ASSOCIATED WITH A GROWTH HORMONEâ€SECRETING PITUITARY ADENOMA. Clinical Endocrinology, 1989, 30, 213-224.	1.2	56
161	Correlation of biochemical parameters with single parathyroid adenoma weight and volume. Head and Neck, 2002, 24, 1000-1003.	0.9	56
162	Ultrastructural features of collagen in thyroid carcinoma tissue observed by polarization second harmonic generation microscopy. Biomedical Optics Express, 2015, 6, 3475.	1.5	56

#	Article	IF	Citations
163	Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma. Thyroid, 2016, 26, 512-517.	2.4	56
164	Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2018, 42, 201-213.	2.1	56
165	Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. Journal of Clinical Investigation, 2002, 110, 973-981.	3.9	56
166	Human Fetal Adenohypophysis: Morphologic and Functional Analysis in vitro. Neuroendocrinology, 1991, 53, 562-572.	1.2	55
167	Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers, 2019, 11, 828.	1.7	55
168	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas, 2021, 50, 469-493.	0.5	55
169	The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone Production. Molecular Endocrinology, 2001, 15, 589-599.	3.7	54
170	Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. European Journal of Immunology, 2007, 37, 2234-2241.	1.6	54
171	Follicular Variant Papillary Thyroid Carcinoma Arising in Struma Ovarii. Endocrine Pathology, 2007, 18, 182-186.	5.2	54
172	Implications of the TCGA Genomic Characterization of Papillary Thyroid Carcinoma for Thyroid Pathology: Does Follicular Variant Papillary Thyroid Carcinoma Exist?. Thyroid, 2015, 25, 1-2.	2.4	54
173	Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 555-560.	1.8	54
174	Intrathyroidal lymphoepithelial cysts of probable branchial origin. Human Pathology, 1994, 25, 1238-1242.	1.1	53
175	EFFECT OF SMS 201â€“995, A LONGâ€ACTING SOMATOSTATIN ANALOGUE, ON THE SECRETION AND MORPHOLOGY OF A PITUITARY GROWTH HORMONE CELL ADENOMA. Clinical Endocrinology, 1987, 26, 395-405.	1.2	52
176	Pituitary cells producing more than one hormone human pituitary adenomas. Trends in Endocrinology and Metabolism, 1989, 1, 104-107.	3.1	52
177	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. Archives of Pathology and Laboratory Medicine, 2014, 138, 182-188.	1.2	52
178	Oncocytomas and null cell adenomas of the human pituitary: Morphometric and in vitro functional comparison. Virchows Archiv A, Pathological Anatomy and Histopathology, 1988, 413, 333-339.	1.4	51
179	Management considerations in HÃ¼rthle cell carcinoma. Surgery, 1995, 118, 711-715.	1.0	50
180	Isolation of a Murine Homologue of the Drosophila neuralized Gene, a Gene Required for Axonemal Integrity in Spermatozoa and Terminal Maturation of the Mammary Gland. Molecular and Cellular Biology, 2001, 21, 7481-7494.	1.1	50

#	Article	IF	Citations
181	When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis. Head and Neck Pathology, 2015, 9, 16-23.	1.3	50
182	The MEN-1 Gene Is Rarely Down-Regulated in Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3210-3212.	1.8	50
183	Acromegaly and Somatotroph Hyperplasia with Adenomatous Transformation Due to Pituitary Metastasis of a Growth Hormone-Releasing Hormone-Secreting Pulmonary Endocrine Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4776-4780.	1.8	49
184	Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications. Molecular Endocrinology, 2006, 20, 2965-2975.	3.7	49
185	Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital. Head and Neck, 2013, 35, 35-39.	0.9	49
186	Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 557-563.	1.4	49
187	HÃ¼rthle Cell Tumors. JAMA Otolaryngology, 2002, 128, 237.	1.5	48
188	Pancreatic Endocrine Pathology in von Hippelâ€“Lindau Disease: An Expanding Spectrum of Lesions. Endocrine Pathology, 2004, 15, 141-148.	5.2	48
189	Therapeutic implications of accurate classification of pituitary adenomas. Seminars in Diagnostic Pathology, 2013, 30, 158-164.	1.0	48
190	Immunohistochemical Biomarkers in Thyroid Pathology. Endocrine Pathology, 2018, 29, 91-112.	5.2	48
191	GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Modern Pathology, 2019, 32, 484-489.	2.9	48
192	Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Laboratory Investigation, 2005, 85, 464-473.	1.7	47
193	The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 4713-4720.	3.2	47
194	Molecular determinants of pituitary cytodifferentiation. , 1999, 1, 159-168.		46
195	1Î±,25-Dihydroxyvitamin D3 Targets PTEN-Dependent Fibronectin Expression to Restore Thyroid Cancer Cell Adhesiveness. Molecular Endocrinology, 2005, 19, 2349-2357.	3.7	46
196	Immunohistochemical study of p53 protein in human and animal pituitary tumors. Endocrine Pathology, 1993, 4, 95-99.	5.2	45
197	Stage-Sensitive Blockade of Pituitary Somatomammotrope Development by Targeted Expression of a Dominant Negative Epidermal Growth Factor Receptor in Transgenic Mice. Molecular Endocrinology, 2001, 15, 600-613.	3.7	45
198	Pituitary Tumor AP-2Î± Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4. Journal of Biological Chemistry, 2003, 278, 19597-19602.	1.6	45

#	Article	IF	Citations
199	The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy. Cancer Research, 2012, 72, 5683-5691.	0.4	45
200	The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Human Pathology, 2018, 74, 1-4.	1.1	45
201	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. Endocrine Pathology, 2018, 29, 137-149.	5.2	45
202	Papillary Carcinoma of Thyroid Metastatic to the Pituitary Gland. Archives of Pathology and Laboratory Medicine, 2001, 125, 935-938.	1.2	45
203	Clinically Non-Functioning Human Pituitary Adenomas. Canadian Journal of Neurological Sciences, 1992, 19, 228-235.	0.3	44
204	Immunohistochemical localization of p53 in human thyroid neoplasms: Correlation with biological behavior. Endocrine Pathology, 1997, 8, 21-28.	5.2	44
205	An essential role for the hematopoietic transcription factor Ikaros in hypothalamicâ€“pituitary-mediated somatic growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2214-2219.	3.3	44
206	Transcript Level Modulates the Inherent Oncogenicity of RET/PTC Oncoproteins. Cancer Research, 2009, 69, 4861-4869.	0.4	44
207	The dangers of parathyroid biopsy. Journal of Otolaryngology - Head and Neck Surgery, 2017, 46, 4.	0.9	44
208	Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Modern Pathology, 2021, 34, 1634-1650.	2.9	44
209	Glucagon and Related Peptides in Fetal Rat Hypothalamusin Vivoandin Vitro*. Endocrinology, 1990, 126, 110-117.	1.4	43
210	Human skin expresses growth hormone but not the prolactin gene. Translational Research, 2000, 136, 476-481.	2.4	43
211	Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clinical Endocrinology, 2001, 55, 549-556.	1.2	43
212	An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocrine Pathology, 2019, 30, 118-127.	5.2	43
213	Molecular Basis of Pituitary Development and Cytogenesis. , 2004, 32, 1-19.		42
214	XB130, a Novel Adaptor Protein, Promotes Thyroid Tumor Growth. American Journal of Pathology, 2011, 178, 391-401.	1.9	42
215	Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Review of Endocrinology and Metabolism, 2016, 11, 149-162.	1.2	42
216	The Clinicopathological Spectrum of Acromegaly. Journal of Clinical Medicine, 2019, 8, 1962.	1.0	42

#	Article	IF	Citations
217	The câ€•erb Bâ€2/ neu protoâ€oncogene in human pituitary tumours. Clinical Endocrinology, 1997, 46, 599-606.	1.2	41
218	Prediction of Malignant Behavior of Pheochromocytomas and Paragangliomas Using Immunohistochemical Techniques. Endocrine Pathology, 2002, 13, 149-156.	5.2	41
219	Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells. Molecular Endocrinology, 2006, 20, 2976-2986.	3.7	41
220	Deoxyribonucleic Acid Methyltransferase 3B Promotes Epigenetic Silencing through Histone 3 Chromatin Modifications in Pituitary Cells. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3610-3617.	1.8	41
221	Ectopic Thyroid Tissue Within the Gall Bladder: Case Report and Brief Review of the Literature. Endocrine Pathology, 2010, 21, 263-265.	5.2	41
222	Immunohistochemical localization of keratin in craniopharyngiomas and squamous cell nests of the human pituitary. Acta Neuropathologica, 1981, 54, 257-260.	3.9	40
223	Pituitary Morphology in Anencephalic Human Fetuses. Neuroendocrinology, 1997, 65, 164-172.	1.2	40
224	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. Molecular Endocrinology, 2002, 16, 1069-1078.	3.7	40
225	Double Adenomas of the Pituitary: Transcription Factors Pit-1, T-pit, and SF-1 Identify Cytogenesis and Differentiation. Endocrine Pathology, 2005, 16, 187-194.	5.2	40
226	The Zinc Finger Ikaros Transcription Factor Regulates Pituitary Growth Hormone and Prolactin Gene Expression through Distinct Effects on Chromatin Accessibility. Molecular Endocrinology, 2005, 19, 1004-1011.	3.7	40
227	Gonadotroph Tumor Associated with Multiple Endocrine Neoplasia Type 1. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 570-574.	1.8	40
228	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Human Pathology, 2007, 38, 1810-1818.	1.1	40
229	Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer. Journal of Clinical Oncology, 2012, 30, 2906-2911.	0.8	40
230	Ikaros integrates endocrine and immune system development. Journal of Clinical Investigation, 2005, 115, 1021-1029.	3.9	39
231	Histological classification of pituitary disease. Clinics in Endocrinology and Metabolism, 1983, 12, 567-596.	1.8	38
232	Immunohistologic Localization of Corticotrophin-Releasing Hormone in Human Tumors. American Journal of Clinical Pathology, 1987, 87, 327-333.	0.4	38
233	Genetics and Proteomics of Pituitary Tumors. Endocrine, 2005, 28, 043-048.	2.2	38
234	Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 727-732.	1.4	38

#	Article	IF	Citations
235	The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression. Endocrine Pathology, 1993, 4, 215-221.	5.2	37
236	Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Endocrine-Related Cancer, 2017, 24, L21-L25.	1.6	37
237	Pituitary acromegaly: not one disease. Endocrine-Related Cancer, 2017, 24, C1-C4.	1.6	37
238	Pancreatic endocrine tumour producing growth hormone-releasing hormone associated with multiple endocrine neoplasia type I syndrome. European Journal of Endocrinology, 1987, 115, 331-337.	1.9	36
239	Controversies in Thyroid Pathology: The Diagnosis of Follicular Neoplasms. Endocrine Pathology, 2008, 19, 156-165.	5.2	36
240	THE PATHOLOGY OF PITUITARY TUMORS. Endocrinology and Metabolism Clinics of North America, 1999, 28, 13-43.	1.2	35
241	A Soluble Dominant Negative Fibroblast Growth Factor Receptor 4 Isoform in Human MCF-7 Breast Cancer Cells. Biochemical and Biophysical Research Communications, 2001, 287, 60-65.	1.0	35
242	Cushing's Syndrome Due to Ectopic CRH Secretion by Adrenal Pheochromocytoma Accompanied by Renal Infarction. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 444-447.	0.6	35
243	Prognostic and Predictive Markers in Medullary Thyroid Carcinoma. Endocrine Pathology, 2012, 23, 232-242.	5.2	35
244	Ikaros integrates endocrine and immune system development. Journal of Clinical Investigation, 2005, 115, 1021-1029.	3.9	35
245	Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3078-3083.	1.8	34
246	Vitamin D and Its Analog EB1089 Induce p27 Accumulation and Diminish Association of p27 with Skp2 Independent of PTEN in Pituitary Corticotroph Cells. Brain Pathology, 2002, 12, 412-419.	2.1	34
247	Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary, 2020, 23, 322-325.	1.6	34
248	Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Human Pathology, 1992, 23, 884-887.	1.1	33
249	Cerebral and cerebellar gangliocytomas: a morphological study of nine cases. Acta Neuropathologica, 1994, 88, 246-251.	3.9	33
250	An unusual association of a sellar gangliocytoma with a prolactinoma. Pituitary, 2008, 11, 85-87.	1.6	33
251	Protocol for the Examination of Specimens From Patients With Primary Pituitary Tumors. Archives of Pathology and Laboratory Medicine, 2011, 135, 640-646.	1.2	33
252	Simian Virus 40 T Antigen-Induced Gonadotroph Adenomas: A Model of Human Null Cell Adenomas¹. Endocrinology, 1998, 139, 3342-3351.	1.4	32

#	Article	IF	Citations
253	AIP Mutations are not Identified in Patients with Sporadic Pituitary Adenomas. Endocrine Pathology, 2007, 18, 76-78.	5.2	32
254	Pitfalls in the Diagnosis of Follicular Epithelial Proliferations of the Thyroid. Advances in Anatomic Pathology, 2012, 19, 363-373.	2.4	32
255	Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?. Thyroid, 2017, 27, 1498-1504.	2.4	32
256	Characterization of Pancreatic Cancer Tissue Using Multiphoton Excitation Fluorescence and Polarization-Sensitive Harmonic Generation Microscopy. Frontiers in Oncology, 2019, 9, 272.	1.3	32
257	Pituitary, Pancreatic and Gut Neuroendocrine Defects in Protein Tyrosine Phosphatase-Sigma-Deficient Mice. Molecular Endocrinology, 2002, 16, 155-169.	3.7	31
258	Xanthomatous Hypophysitis Is Associated with Ruptured Rathkeâ€™s Cleft Cyst. Endocrine Pathology, 2017, 28, 83-90.	5.2	31
259	Reversible sellar enlargement due to growth hormone-releasing hormone production by pancreatic endocrine tumors in an acromegalic patient with multiple endocrine neoplasia type I syndrome. Cancer, 1988, 62, 445-450.	2.0	30
260	Malignant Teratoma of the Thyroid: Aggressive Chemoradiation Therapy is Required After Surgery. Thyroid, 2003, 13, 401-404.	2.4	30
261	Histone-Acetylated Control of Fibroblast Growth Factor Receptor 2 Intron 2 Polymorphisms and Isoform Splicing in Breast Cancer. Molecular Endocrinology, 2009, 23, 1397-1405.	3.7	30
262	Development of a molecular-beacon-based multi-allelic real-time RT-PCR assay for the detection of human coronavirus causing severe acute respiratory syndrome (SARS-CoV): a general methodology for detecting rapidly mutating viruses. Archives of Virology, 2011, 156, 671-680.	0.9	30
263	The Role of Mediators of Cell Invasiveness, Motility, and Migration in the Pathogenesis of Silent Corticotroph Adenomas. Endocrine Pathology, 2013, 24, 191-198.	5.2	30
264	Rhabdoid Tumor of the Thyroid Gland: A Variant of Anaplastic Carcinoma. Archives of Pathology and Laboratory Medicine, 2005, 129, e55-e57.	1.2	30
265	Regulation of Peptide-YY Synthesis and Secretion in Fetal Rat Intestinal Cultures*. Endocrinology, 1991, 129, 3351-3358.	1.4	29
266	Ectopic ACTH Syndrome: Discrepancy between Somatostatin Receptor Status in vivo and ex vivo, and between Immunostaining and Gene Transcription for POMC and CRH. Hormone Research in Paediatrics, 2002, 57, 200-204.	0.8	29
267	Case Report: Adrenal LH/hCG Receptor Overexpression and Gene Amplification Causing Pregnancy-Induced Cushingâ€™s Syndrome. Endocrine Pathology, 2009, 20, 256-261.	5.2	29
268	Hormone profiling, WHO 2010 grading, and AJCC / UICC staging in pancreatic neuroendocrine tumor behavior. Cancer Medicine, 2013, 2, 701-711.	1.3	29
269	Integrated Pathology Informatics Enables High-Quality Personalized and Precision Medicine: Digital Pathology and Beyond. Archives of Pathology and Laboratory Medicine, 2018, 142, 369-382.	1.2	29
270	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. , 0, .		29

#	Article	IF	Citations
271	Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippelâ€“Lindau disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 593-597.	1.4	28
272	Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocrine Pathology, 2018, 29, 332-338.	5.2	28
273	Molecular interactions during pregnancy. Molecular Human Reproduction, 1996, 2, 457-461.	1.3	27
274	Thyroid Gland: International Case Conference. Endocrine Pathology, 2002, 13, 131-134.	5.2	27
275	Ikaros Modulates Cholesterol Uptake: A Link between Tumor Suppression and Differentiation. Cancer Research, 2008, 68, 3715-3723.	0.4	27
276	Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. Molecular and Cellular Endocrinology, 2018, 469, 70-76.	1.6	27
277	Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas. Modern Pathology, 2008, 21, 856-865.	2.9	26
278	Epigenetic Dysregulation in Thyroid Neoplasia. Endocrinology and Metabolism Clinics of North America, 2008, 37, 389-400.	1.2	26
279	Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism. Endocrine Pathology, 2016, 27, 25-33.	5.2	26
280	Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses. American Journal of Surgical Pathology, 2017, 41, 525-534.	2.1	26
281	Immunohistochemical Biomarkers in Pituitary Pathology. Endocrine Pathology, 2018, 29, 130-136.	5.2	26
282	Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 169-191.	5.2	26
283	Evaluation of the WHO 2010 Grading and AJCC/UICC Staging Systems in Prognostic Behavior of Intestinal Neuroendocrine Tumors. PLoS ONE, 2013, 8, e61538.	1.1	26
284	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Seminars in Diagnostic Pathology, 2009, 26, 165-176.	1.0	25
285	FGFR2 Isoforms Support Epithelialâ€“Stromal Interactions in Thyroid Cancer Progression. Cancer Research, 2012, 72, 2017-2027.	0.4	25
286	Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. European Journal of Endocrinology, 2016, 174, 307-314.	1.9	25
287	The Clinicopathological Spectrum of Parathyroid Carcinoma. Frontiers in Endocrinology, 2019, 10, 731.	1.5	25
288	Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon. Endocrine Pathology, 2019, 30, 74-80.	5.2	25

#	Article	IF	Citations
289	Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocrine Pathology, 2021, 32, 327-335.	5.2	25
290	Expression of activin/inhibin subunit messenger ribonucleic acids by gonadotroph adenomas. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1399-1403.	1.8	25
291	The Ontogeny of Pit-1 Expression in the Human Fetal Pituitary Gland. Neuroendocrinology, 1996, 63, 349-355.	1.2	24
292	Aldosterone-Producing Adrenal Cortical Adenoma with Oncocytic Change and Cytoplasmic Eosinophilic Globular Inclusions. Endocrine Pathology, 2009, 20, 182-185.	5.2	24
293	The epigenetic landscape of differentiated thyroid cancer. Molecular and Cellular Endocrinology, 2018, 469, 3-10.	1.6	24
294	What's new in pituitary pathology?. Histopathology, 2018, 72, 133-141.	1.6	24
295	A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. Endocrine Pathology, 2019, 30, 201-218.	5.2	24
296	Hypothalamic Vasopressin-Producing Tumors. American Journal of Surgical Pathology, 2019, 43, 251-260.	2.1	24
297	Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocrine Pathology, 2020, 31, 330-336.	5.2	24
298	Decreased follistatin gene expression in gonadotroph adenomas. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3397-3403.	1.8	24
299	Thyroid thymoma in childhood. Endocrine Pathology, 1990, 1, 123-127.	5.2	23
300	Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly. Clinical Endocrinology, 2001, 55, 135-140.	1.2	23
301	FGF Receptor Signaling at the Crossroads of Endocrine Homeostasis and Tumorigenesis. Hormone and Metabolic Research, 2005, 37, 355-360.	0.7	23
302	Composite Pituitary Adenoma and Craniopharyngioma?. American Journal of Surgical Pathology, 2008, 32, 1736-1741.	2.1	23
303	CtBP1 Interacts with Ikaros and Modulates Pituitary Tumor Cell Survival and Response to Hypoxia. Molecular Endocrinology, 2012, 26, 447-457.	3.7	23
304	The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-Î²B Signaling. Molecular and Cellular Biology, 2012, 32, 4662-4673.	1.1	23
305	Modeling complexity in pathologist workload measurement: the Automatable Activity-Based Approach to Complexity Unit Scoring (AABACUS). Modern Pathology, 2015, 28, 324-339.	2.9	23
306	Clinical Applications of Whole-slide Imaging in Anatomic Pathology. Advances in Anatomic Pathology, 2017, 24, 215-221.	2.4	23

#	Article	IF	Citations
307	Endocrine pathology: past, present and future. Pathology, 2018, 50, 111-118.	0.3	23
308	Ki67 Quantitative Interpretation: Insights using Image Analysis. Journal of Pathology Informatics, 2019, 10, 8.	0.8	23
309	Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary. Virchows Archiv A, Pathological Anatomy and Histopathology, 1990, 417, 361-367.	1.4	22
310	Changes in hormone production of a recurrent silent corticotroph adenoma of the pituitary: A histologic, immunohistochemical, ultrastructural, and tissue culture study. Human Pathology, 1991, 22, 719-721.	1.1	22
311	Medullary thyroid carcinoma metastatic to the pituitary gland: an unusual site of metastasis. Annals of Diagnostic Pathology, 2008, 12, 199-203.	0.6	22
312	Solitary Fibrous Tumor of the Sella Mimicking Pituitary Adenoma: An Uncommon Tumor in a Rare Locationâ€"A Case Report. Endocrine Pathology, 2009, 20, 56-61.	5.2	22
313	Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. Thyroid, 2019, 29, 619-624.	2.4	22
314	Sellar Glomangioma. Ultrastructural Pathology, 1984, 7, 49-54.	0.4	21
315	Intermediate Filaments in the Human Pituitary Gland: An Immunohistochemical Study. Canadian Journal of Neurological Sciences, 1990, 17, 131-136.	0.3	21
316	Pituitary Adenoma with "Honeycomb Golgi" Appearance Showing a Phenotypic Change at Recurrence from Clinically Nonfunctioning to Typical Cushing Disease. Endocrine Pathology, 2002, 13, 125-130.	5.2	21
317	TTF-1 Expressing Sellar Neoplasm with Ependymal Rosettes and Oncocytic Change: Mixed Ependymal and Oncocytic Variant Pituicytoma. Endocrine Pathology, 2014, 25, 436-438.	5.2	21
318	Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 83-97.	1.1	21
319	Cytokeratin profiles in pituitary neuroendocrine tumors. Human Pathology, 2021, 107, 87-95.	1.1	21
320	Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. Endocrine Pathology, 2021, 32, 77-101.	5.2	21
321	Composite Adenomatoid Tumor and Myelolipoma of Adrenal Gland: Report of 2 Cases. Archives of Pathology and Laboratory Medicine, 2008, 132, 265-267.	1.2	21
322	Report of a case of pheochromocytoma producing immunoreactive ACTH and beta-endorphin. Journal of Endocrinological Investigation, 1984, 7, 117-122.	1.8	20
323	Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation. Journal of Endocrinological Investigation, 1989, 12, 443-448.	1.8	20
324	Cytoplasmic staining oferbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clinical Endocrinology, 1998, 49, 629-637.	1.2	20

#	Article	IF	Citations
325	Chromatin remodeling and histone modifications in pituitary tumors. Molecular and Cellular Endocrinology, 2010, 326, 66-70.	1.6	20
326	The evolution of differentiated thyroid cancer. Pathology, 2017, 49, 229-237.	0.3	20
327	Sp1-Mediated Transcriptional Control of Fibroblast Growth Factor Receptor 4 in Sarcomas of Skeletal Muscle Lineage. Clinical Cancer Research, 2004, 10, 6750-6758.	3.2	19
328	Pancreatic Endocrine Tumors. Advances in Anatomic Pathology, 2004, 11, 202-210.	2.4	19
329	Ikaros Is Regulated through Multiple Histone Modifications and Deoxyribonucleic Acid Methylation in the Pituitary. Molecular Endocrinology, 2007, 21, 1205-1215.	3.7	19
330	The emerging role of the Ikaros stem cell factor in the neuroendocrine system. Journal of Molecular Endocrinology, 2008, 41, 45-51.	1.1	19
331	Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. Frontiers in Endocrinology, 2018, 9, 641.	1.5	19
332	Characterization of pathological thyroid tissue using polarization-sensitive second harmonic generation microscopy. Laboratory Investigation, 2020, 100, 1280-1287.	1.7	19
333	Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas. American Journal of Surgical Pathology, 2021, 45, 1264-1273.	2.1	19
334	Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study. Endocrine Pathology, 1990, 1, 228-235.	5.2	18
335	Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro. European Journal of Endocrinology, 1993, 129, 565-572.	1.9	18
336	ref/PTC-1, -2, and -3 Oncogene Rearrangements in Human Thyroid Carcinomas: Implications for Metastatic Potential?. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1306-a-1307.	1.8	18
337	Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clinica Chimica Acta, 2000, 300, 171-180.	0.5	18
338	Hyalinizing Trabecular Tumor of the Thyroid Gland. American Journal of Clinical Pathology, 2004, 122, 495-496.	0.4	18
339	Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. Endocrine-Related Cancer, 2009, 16, 455-466.	1.6	18
340	FGFR4 Polymorphic Variants Modulate Phenotypic Features of Cushing Disease. Molecular Endocrinology, 2014, 28, 525-533.	3.7	18
341	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. Annals of Surgical Oncology, 2019, 26, 2533-2539.	0.7	18
342	Oncocytic Change in Thyroid Pathology. Frontiers in Endocrinology, 2021, 12, 678119.	1.5	18

#	Article	IF	Citations
343	Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Research, 2010, 30, 1681-8.	0.5	18
344	Pituitary corticotroph adenoma with crookeâ€™s hyalinization. Endocrine Pathology, 1991, 2, 111-116.	5.2	17
345	A composite somatotroph-corticotroph pituitary adenoma. Endocrine Pathology, 1994, 5, 240-246.	5.2	17
346	How Familial Cancer Genes and Environmentally Induced Oncogenes Have Changed the Endocrine Landscape. Modern Pathology, 2001, 14, 246-253.	2.9	17
347	Intracytoplasmic Inclusions (Including the So-Called "Rhabdoid" Phenotype) in Pancreatic Endocrine Tumors. Endocrine Pathology, 2006, 17, 75-82.	5.2	17
348	â€œNext-Generationâ€•Pathology and Laboratory Medicine. Archives of Pathology and Laboratory Medicine, 2011, 135, 1531-1532.	1.2	17
349	The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression. Oncogene, 2012, 31, 4012-4021.	2.6	17
350	Defining diagnostic tissue in the era of personalized medicine. Cmaj, 2013, 185, 135-139.	0.9	17
351	Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Modern Pathology, 2014, 27, 1050-1062.	2.9	17
352	ret/PTC-1, -2, and -3 Oncogene Rearrangements in Human Thyroid Carcinomas: Implications for Metastatic Potential?. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1306-1306.	1.8	17
353	Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. Modern Pathology, 2022, 35, 712-720.	2.9	17
354	Medical management of pituitary adenomas: structural and ultrastructural changes. Pituitary, 2002, 5, 133-139.	1.6	16
355	"Honeycomb Golgi" in Pituitary Adenomas: Not a Marker of Gonadotroph Adenomas. Endocrine Pathology, 2003, 14, 363-368.	5.2	16
356	Management of Lesions of the Pituitary Stalk and Hypothalamus. , 2003, 13, 38-51.		16
357	Ependymoma of the pituitary fossa. Journal of Neurosurgery, 2006, 105, 616-620.	0.9	16
358	Mice lacking the transcription factor Ikaros display behavioral alterations of an anti-depressive phenotype. Experimental Neurology, 2008, 211, 107-114.	2.0	16
359	Leydig Cell Hyperplasia Due to a Testicular Embryonal Carcinoma Producing Human Chorionic Gonadotropin. Andrologia, 1984, 16, 146-155.	1.0	16
360	Functional Cardiac Paraganglioma Associated with a Rare SDHC Mutation. Endocrine Pathology, 2014, 25, 315-320.	5.2	16

#	Article	IF	Citations
361	Comprehensive characterization of a Canadian cohort of von Hippelâ€Lindau disease patients. Clinical Genetics, 2019, 96, 461-467.	1.0	16
362	Malignant Pheochromocytoma Secreting Vasoactive Intestinal Peptide and Response to Sunitinib: A Case Report and Literature Review. Endocrine Practice, 2014, 20, e145-e150.	1.1	15
363	Hypothalamic Endocrine Tumors: An Update. Journal of Clinical Medicine, 2019, 8, 1741.	1.0	15
364	Middle Ear â€œAdenomaâ€• a Neuroendocrine Tumor with Predominant L Cell Differentiation. Endocrine Pathology, 2021, 32, 433-441.	5.2	15
365	An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. Journal of Clinical Medicine, 2021, 10, 2254.	1.0	15
366	Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?. Endocrine Pathology, 2021, 32, 3-16.	5.2	15
367	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. , 0, .		15
368	High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. Oncotarget, 2016, 7, 19948-19959.	0.8	15
369	Pituitary Pathology in Acromegaly. Endocrinology and Metabolism Clinics of North America, 1992, 21, 553-574.	1.2	14
370	Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells. Laboratory Investigation, 2004, 84, 1571-1580.	1.7	14
371	Complex Endocrinopathies in MEN-1: Diagnostic Dilemmas in Endocrine Oncology. Endocrine Pathology, 2007, 18, 37-41.	5.2	14
372	Development of a pituitaryâ€specific cre line targeted to the Pitâ€1 lineage. Genesis, 2008, 46, 37-42.	0.8	14
373	Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. Laboratory Investigation, 2011, 91, 147-156.	1.7	14
374	Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 4-17.	0.1	14
375	Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. Endocrine Pathology, 2016, 27, 97-103.	5.2	14
376	FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. Oncotarget, 2017, 8, 3481-3494.	0.8	14
377	Human Pituitary Corticotroph Adenomas in vitro: Morphologic and Functional Responses to Corticotropin-Releasing Hormone and Cortisol. Neuroendocrinology, 1990, 51, 241-248.	1.2	13
378	Plurihormonality in Pituitary Adenomas Associated with Acromegaly. Endocrine Pathology, 2006, 17, 291-296.	5.2	13

#	Article	IF	Citations
379	Osteopontin stimulates invasion of NCIâ€h295 cells but is not associated with survival in adrenocortical carcinoma. Journal of Pathology, 2009, 218, 232-240.	2.1	13
380	Metastatic Neuroendocrine Neoplasms of Unknown Primary Site. , 2021, , 357-387.		13
381	Expression of p53 in Inverted Papilloma and Malignancy Associated with Inverted Papilloma. The Journal of Otolaryngology, 2003, 32, 048.	0.6	13
382	Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E490-E495.	1.8	12
383	Dopaminergic Resistant Prolactinomas in the Peripubertal Population. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 951-3.	0.4	12
384	Morphological distinction of cortisolâ€producing and aldosteroneâ€producing adrenal cortical adenomas: not only possible but a critical clinical responsibility. Histopathology, 2012, 60, 1015-1016.	1.6	12
385	Recurrent Acute-Onset Cushingâ€™s Syndrome 6ÂYears after Removal of a Thymic Neuroendocrine Carcinoma: From Ectopic ACTH to CRH. Endocrine Pathology, 2013, 24, 25-29.	5.2	12
386	Inter-Observer Variation in the Pathologic Identification of Extranodal Extension in Nodal Metastasis from Papillary Thyroid Carcinoma. Thyroid, 2016, 26, 816-819.	2.4	12
387	Controversies in Papillary Microcarcinoma of the Thyroid. Endocrine Pathology, 2003, 14, 183-192.	5.2	12
388	2020 Vision of Digital Pathology in Action. Journal of Pathology Informatics, 2019, 10, 27.	0.8	12
389	CEACAM1 Expression in Pancreatic Endocrine Tumors. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 286-293.	0.6	11
390	Molecular pathology of thyroid cancer. Diagnostic Histopathology, 2011, 17, 124-139.	0.2	11
391	Metabolic Glucose Status and Pituitary Pathology Portend Therapeutic Outcomes in Acromegaly. PLoS ONE, 2013, 8, e73543.	1.1	11
392	Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome. Frontiers in Endocrinology, 2021, 12, 795184.	1.5	11
393	Nutrient and Peptide Regulation of Somatostatin-28 Secretion from Intestinal Cultures¹. Endocrinology, 1998, 139, 148-155.	1.4	10
394	The Mindâ€™s Eye. American Journal of Clinical Pathology, 2001, 116, 635-636.	0.4	10
395	Is Granulomatous Thyroiditis a Complication of Breast Implants?. Endocrine Pathology, 2002, 13, 239-244.	5.2	10
396	Pseudopheochromocytoma of Pregnancy. Endocrine Practice, 2003, 9, 376-379.	1.1	10

#	Article	IF	Citations
397	Cellâ€“cell communication in the pituitary: orchestrator of pulsatile growth hormone secretion?. Trends in Endocrinology and Metabolism, 2006, 17, 299-300.	3.1	10
398	Transgenic and Knockout Mouse Models Clarify Pituitary Development, Function and Disease. Brain Pathology, 2001, 11, 370-383.	2.1	10
399	Myelolipoma with Adrenocortical Adenoma: An unusual Combination that can Resemble Carcinoma. Endocrine Pathology, 2007, 18, 103-105.	5.2	10
400	Ectopic Growth Hormone-Releasing Hormone Secretion by a Neuroendocrine Tumor Causing Acromegaly: Long-Term Follow-Up Results. Endocrine Pathology, 2009, 20, 127-132.	5.2	10
401	Composite Medullary and Papillary Thyroid Carcinoma In a Patient With MEN 2B. , 2009, 14, 208-213.		10
402	Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome. Endocrine Pathology, 2012, 23, 254-259.	5.2	10
403	Genomic Approaches to Problems in Pituitary Neoplasia. Endocrine Pathology, 2014, 25, 209-213.	5.2	10
404	Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors. World Neurosurgery, 2021, 146, e341-e350.	0.7	10
405	Left Atrial Myxoma Presenting as Migraine With Aura: A VIPâ€induced Syndrome?. Headache, 2005, 45, 251-254.	1.8	9
406	Microadenomatosis of the Pancreas in von Hippel-Lindau Disease. American Journal of Surgical Pathology, 2006, 30, 1630.	2.1	9
407	Sellar Glomangioma. Endocrine Pathology, 2011, 22, 218-221.	5.2	9
408	The Rationale of Patients with Early-Stage Papillary Thyroid Cancer for Accepting or Rejecting Radioactive Iodine Remnant Ablation. Thyroid, 2013, 23, 246-247.	2.4	9
409	Metastatic Thyroid Carcinoma to the Gastric Body. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3958-3959.	1.8	9
410	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Thyroid Carcinoma. Archives of Pathology and Laboratory Medicine, 2017, 141, 559-563.	1.2	9
411	TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica. Endocrine Pathology, 2017, 28, 22-26.	5.2	9
412	Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin. Endocrine Pathology, 2018, 29, 15-20.	5.2	9
413	An Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory Carcinoma. Frontiers in Endocrinology, 2018, 9, 555.	1.5	9
414	Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. Genome Medicine, 2020, 12, 38.	3.6	9

#	Article	IF	Citations
415	The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research. Endocrine Pathology, 2021, 32, 415-417.	5.2	9
416	An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140105.	0.2	9
417	The endocrine pancreas and its tumors. Endocrine Pathology, 1993, 4, 120-130.	5.2	8
418	Diseases of the Pituitary. Neurosurgery Clinics of North America, 1994, 5, 71-95.	0.8	8
419	Genetic abnormalities of the endothelium. Microscopy Research and Technique, 2003, 60, 30-37.	1.2	8
420	Thyroid neoplasms of follicular cell derivation: A simplified approach. Seminars in Diagnostic Pathology, 2013, 30, 178-185.	1.0	8
421	Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy. , 2015, , .		8
422	NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells. Endocrine-Related Cancer, 2016, 23, 445-456.	1.6	8
423	Images in Endocrine Pathology: Progressive Loss of Sustentacular Cells in a Case of Recurrent Jugulotympanic Paraganglioma over a Span of 5 years. Endocrine Pathology, 2020, 31, 310-314.	5.2	8
424	Stage-Sensitive Blockade of Pituitary Somatomammotrope Development by Targeted Expression of a Dominant Negative Epidermal Growth Factor Receptor in Transgenic Mice. , 0, .		8
425	Genetic Events in the Evolution of Thyroid Cancer. The Journal of Otolaryngology, 2002, 31, 202.	0.6	8
426	Plurihormonal pituitary tumors: Beyond the one cell-one hormone theory. Endocrine Pathology, 1993, 4, 1-3.	5.2	7
427	C-Cell Lesions of the Thyroid. , 1997, 2, 210-217.		7
428	Granulomatous Hypophysitis with Psammoma Bodies: A Diagnostic Dilemma. Endocrine Pathology, 2004, 15, 359-364.	5.2	7
429	Pancreatic endocrine tumour with ductules: further observations of an unusual histological subtype. Pathology, 2006, 38, 5-9.	0.3	7
430	Silent Corticotroph Adenoma with Adrenal Cortical Choristoma: a Rare but Distinct Morphological Entity. Endocrine Pathology, 2013, 24, 162-166.	5.2	7
431	Somatostatin Receptor Ligand Therapyâ€"A Potential Therapy for Neurocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2395-2402.	1.8	7
432	Immunohistochemical Analysis of the Metabolic Phenotype of Adrenal Cortical Carcinoma. Endocrine Pathology, 2020, 31, 231-238.	5.2	7

#	Article	IF	Citations
433	Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 222-227.	5.2	7
434	Genetic and epigenetic characterization of posterior pituitary tumors. Acta Neuropathologica, 2021, 142, 1025-1043.	3.9	7
435	Hyalinizing trabecular tumor of the thyroid gland: much ado about nothing?. American Journal of Clinical Pathology, 2004, 122, 495-6.	0.4	7
436	Hashimotoâ€™s thyroiditis with granulomas: A unifying immunological etiology?. Endocrine Pathology, 1992, 3, 52-57.	5.2	6
437	Multiple Endocrine Neoplasia Type 1. , 2014, 19, 85-89.		6
438	Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease. Frontiers in Endocrinology, 2021, 12, 620005.	1.5	6
439	Papillary Thyroid Carcinoma and Variants. , 2010, , 91-116.		6
440	The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Modern Pathology, 2022, 35, 1570-1577.	2.9	6
441	In vitro studies of human pituitary adenomas. Pathology Research and Practice, 1988, 183, 561-564.	1.0	5
442	A serum-free system for primary cultures of human pituitary adenomas. Endocrine Pathology, 1995, 6, 289-299.	5.2	5
443	Angiopoietins Are Expressed in the Normal Rat Pituitary Gland. Endocrine Pathology, 2005, 16, 067-074.	5.2	5
444	Anaplastic Carcinoma of the Thyroid Gland. , 2005, , 159-167.		5
445	The Pathology of Thyroid Cancer. Cancer Treatment and Research, 2005, 122, 23-68.	0.2	5
446	Creation of a retrospective searchable neuropathologic database from print archives at Toronto's University Health Network. Laboratory Investigation, 2008, 88, 89-93.	1.7	5
447	Images in Endocrine Pathology: Thyrotoxicosis Associated with Destructive Thyroiditis. Endocrine Pathology, 2012, 23, 212-214.	5.2	5
448	XB130 Deficiency Causes Congenital Hypothyroidism in Mice due to Disorganized Apical Membrane Structure and Function of Thyrocytes. Thyroid, 2021, 31, 1650-1661.	2.4	5
449	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular Biology, 2022, 44, 2015-2028.	1.0	5
450	The adrenal cortex in ectopic adrenocorticotropic hormone syndrome: A morphological study with histology, transmission and scanning electron microscopy, flow cytometry, and image analysis. Endocrine Pathology, 1990, 1, 183-191.	5.2	4

#	Article	IF	Citations
451	Silent corticotroph adenoma with multiple cysts: Pars intermedia tumor?. Endocrine Pathology, 1992, 3, 47-51.	5.2	4
452	Granulomatous and lymphocytic thyroiditis associated with a follicular adenoma. Endocrine Pathology, 1992, 3, 105-109.	5.2	4
453	Is Adrenal Ovarian Thecal Metaplasia a Misnomer? Report of Three Cases of Radial Scar-Like Spindle Cell Myofibroblastic Nodule of the Adrenal Gland. Endocrine Pathology, 2011, 22, 222-225.	5.2	4
454	Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function. Molecular and Cellular Endocrinology, 2017, 439, 126-132.	1.6	4
455	Noninvasive Follicular Thyroid Neoplasm with Papillaryâ€Like Nuclear Features (NIFTP): Trading Six for a Risky Half Dozen: Reply. World Journal of Surgery, 2018, 42, 2279-2279.	0.8	4
456	The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary. Molecular and Cellular Endocrinology, 2018, 461, 188-193.	1.6	4
457	VEGFRâ€2 is downregulated in sestamibiâ€negative parathyroid adenomas. Head and Neck, 2019, 41, 3564-3569.	0.9	4
458	Thyroid Tumor Capsular Invasion: the Bottom Line or Much Ado About Nothing?. Endocrine Pathology, 2020, 31, 141-142.	5.2	4
459	Follicular cells in pituitary neuroendocrine tumors. Human Pathology, 2021, 114, 1-8.	1.1	4
460	Nasopharyngeal neuroendocrine neoplasms: Systematic review of the literature and case presentation. Journal of Neuroendocrinology, 2021, 33, e13005.	1.2	4
461	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. Journal of Clinical Oncology, 2015, 33, 2594-2594.	0.8	4
462	Issues to Consider When Implementing Digital Pathology for Primary Diagnosis. Archives of Pathology and Laboratory Medicine, 2020, 144, 1297-1297.	1.2	4
463	Cytogenesis of nonfunctioning pituitary adenomas. Endocrine Pathology, 1991, 2, 177-179.	5.2	3
464	Immunohistochemical localization of metal binding proteins in thyroid tissues and tumors. Endocrine Pathology, 1992, 3, 182-187.	5.2	3
465	Pancreatic xanthomatous neuropathy associated with hyperlipidemia: A cause of abdominal pain mimicking chronic pancreatitis. Human Pathology, 1993, 24, 1023-1025.	1.1	3
466	HLA-D antigen expression and Langerhans' cell infiltrates in thyroid tumors. Endocrine Pathology, 1995, 6, 197-206.	5.2	3
467	Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament .. Clinical Endocrinology, 1999, 51, 671-671.	1.2	3
468	Pancreatic Endocrine Tumors With Ductules. American Journal of Surgical Pathology, 2005, 29, 136-137.	2.1	3

#	Article	IF	Citations
469	Preface. Endocrinology and Metabolism Clinics of North America, 2008, 37, xvii-xviii.	1.2	3
470	GNAq Mutations are Not Identified in Papillary Thyroid Carcinomas and Hyperfunctioning Thyroid Nodules. Endocrine Pathology, 2010, 21, 250-252.	5.2	3
471	A Case Report and Review of Hyperprolactinemia that is not Prolactinoma. Canadian Journal of Neurological Sciences, 2011, 38, 652-655.	0.3	3
472	A History of Pituitary Pathology. Endocrine Pathology, 2014, 25, 6-11.	5.2	3
473	Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP. , 2015, , 125-139.		3
474	Cytology and Pathology: Pitfalls and Challenges. , 2016, , 33-46.		3
475	Gonadotrope Tumors. Progress in Molecular Biology and Translational Science, 2016, 143, 187-210.	0.9	3
476	Letter to the Editor From Asa and Mete: â€œHypophysitis, the Growing Spectrum of a Rare Pituitary Diseaseâ€. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2649-e2649.	1.8	3
477	Pituitary carcinoma: reclassification and implications in the NET schema. Endocrine Oncology, 2022, 2, R14-R23.	0.1	3
478	Why? What? Where?. Endocrine Pathology, 1990, 1, 1-3.	5.2	2
479	Utilization of electron microscopic techniques in the in vitro study of adenohypophysial function and regulation. Microscopy Research and Technique, 1992, 20, 136-151.	1.2	2
480	Clinicopathological variations in cushingâ€™s syndrome. Endocrine Pathology, 1999, 10, 165-171.	5.2	2
481	Ductules in Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology, 2004, 28, 417.	2.1	2
482	Adenohypophysitis in rat pituitary allografts. International Journal of Experimental Pathology, 2010, 91, 445-450.	0.6	2
483	Pancreatic Struma with Papillary Thyroid Carcinoma: a Diagnostic Dilemma. Endocrine Pathology, 2017, 28, 91-94.	5.2	2
484	Syndrome of Inappropriate Antidiuresis in a Young Adultâ€”Searching for the Causative Needle in the Proverbial Haystack. Kidney International Reports, 2020, 5, 231-234.	0.4	2
485	Images in Endocrine Pathology: High-Grade Intrathyroidal Parathyroid Carcinoma with Crookeâ€™s Hyalinization. Endocrine Pathology, 2020, 31, 190-194.	5.2	2
486	Hypothalamic hormone-producing tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 181, 67-74.	1.0	2

#	Article	IF	Citations
487	Pituitary. , 2009, , 1949-1983.		2
488	Neuroendocrine Neoplasms: Historical Background and Terminologies. , 2021, , 1-14.		2
489	Pituitary Neuroendocrine Neoplasms. , 2021, , 55-83.		2
490	Thyroid Neuroendocrine Neoplasms. , 2021, , 119-136.		2
491	The Next Steps for Endocrine Pathology. Endocrine Pathology, 2022, 33, 228-230.	5.2	2
492	Pathogenesis of multinodular goiter in elderly XB130 deficient mice: alteration of thyroperoxidase affinity with iodide and hydrogen peroxide. Thyroid, 2021, , .	2.4	2
493	Histological, immunohistochemical, and ultrastructural features of a rat medullary thyroid carcinoma transfected with a corticotropin-releasing hormone cDNA expression vector. Endocrine Pathology, 1992, 3, 39-46.	5.2	1
494	Absence of somatotrophs, lactotrophs, and thyrotrophs in the pituitary of two dwarfs with hypothyroidism: Deficiency of pituitary transcription factor-1?. Endocrine Pathology, 1992, 3, 93-98.	5.2	1
495	Clinical Significance of In Situ Hybridization. Experimental and Clinical Endocrinology and Diabetes, 1993, 101, 46-52.	0.6	1
496	The Classification of Pituitary Tumors: An Update. Seminars in Neurosurgery, 2001, 12, 273-288.	0.0	1
497	Growth Hormone Deficiency and Physical Function. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1839-1846.	1.8	1
498	Conclusion. Modern Pathology, 2001, 14, 261-262.	2.9	1
499	Parathyroid Pathology: A Practical Approach. , 2003, 8, 34-41.		1
500	Familial Pituitary Adenomas and Loss of Function of AIP. Advances in Anatomic Pathology, 2007, 14, 58-59.	2.4	1
501	Adrenal Gland. , 2010, , 461-485.		1
502	The evolving landscape of endocrine pathology practice. Seminars in Diagnostic Pathology, 2013, 30, 157.	1.0	1
503	Editorial: The Birth of Endocrine Pathology. Endocrine Pathology, 2014, 25, 2-2.	5.2	1
504	Genetics and Epigenetics of Endocrine Neoplasia. Molecular and Cellular Endocrinology, 2014, 386, 1.	1.6	1

#	Article	IF	Citations
505	Synchronous Papillary Carcinoma of Thyroid and Lung. Endocrine Pathology, 2016, 27, 268-270.	5.2	1
506	Malignant Ovarian Steroid Cell Tumor Causing Severe Hyperandrogenism: Case Report And Review Of The Literature. AACE Clinical Case Reports, 2017, 3, e269-e274.	0.4	1
507	Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. Head and Neck Pathology, 2021, 15, 628-637.	1.3	1
508	Pendred Syndrome with C Cell Hyperplasia. Endocrine Pathology, 2021, 32, 427-428.	5.2	1
509	Targeted expression of a human pituitary tumorâ€“derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation, 2015, 125, 3303-3303.	3.9	1
510	New Diagnostic and Management Approaches in Endocrine Pathology. Archives of Pathology and Laboratory Medicine, 2008, 132, 1228-1230.	1.2	1
511	Paragangliomas and Pheochromocytomas. , 2021, , 263-285.		1
512	Expression of nm23 antimetastatic gene product in parathyroid hyperplasia, adenoma and carcinoma. An immunohistological assessment. Journal of King Abdulaziz University, Islamic Economics, 2005, 26, 728-31.	0.5	1
513	The pituitary gland. , 0, , 2860-2898.		1
514	Lymphocytic Hypophysitis of Pregnancy Resulting in Hypopituitarism. Obstetrical and Gynecological Survey, 1982, 37, 175-176.	0.2	0
515	Short-term morphologic and functional effects of bromocriptine on pituitary prolactin cell adenomas in vitro. Endocrine Pathology, 1993, 4, 79-85.	5.2	0
516	The first four years of endocrine pathology. Endocrine Pathology, 1994, 5, 79-80.	5.2	0
517	Thyroid lymphomas in human thyroid tissue with autoimmune thyroid disease xenografted in severe combined immunodeficient mice. Endocrine Pathology, 1994, 5, 169-177.	5.2	0
518	Editorial announcement. Endocrine Pathology, 1994, 5, 197-197.	5.2	0
519	Heat-shock stress-response proteins in endocrine pathology. Endocrine Pathology, 1995, 6, 3-11.	5.2	0
520	The Pathophysiology of Pituitary Tumors. Seminars in Neurosurgery, 2001, 12, 261-272.	0.0	0
521	Hypothalamic Disease. , 2004, , 678-687.		0
522	Current views on pathogenesis of pituitary tumors. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 281-286.	0.6	0

#	Article	IF	Citations
523	Images in Endocrine Pathology: Lipoadenoma-like Cystic Epithelial Lesion in the Lateral Neck. Endocrine Pathology, 2011, 22, 229-231.	5.2	0
524	Mechanisms of pituitary tumorigenesis. , 0, , 652-668.		0
525	In Reply. Archives of Pathology and Laboratory Medicine, 2015, 139, 967-968.	1.2	0
526	Molecular Pathogenesis of Pituitary Tumors. , 2017, , 165-175.		0
527	Hypothalamic Disease. , 2017, , 97-106.		0
528	Pituitary Tumors; Diagnosis and Treatment. , 2018, , 257-257.		0
529	Molecular Predictors of Clinical Behavior in Pituitary Adenohypophysial Tumors. Contemporary Endocrinology, 2019, , 155-172.	0.3	0
530	Pathology of pituitary growth hormone excess. , 2021, , 17-37.		0
531	Pituitary corticotroph tumour with adrenocortical cells: A distinct clinicopathologic entity with unique morphology and methylation profile. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	0
532	Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies. Neuro-Oncology, 2021, 23, 1803-1804.	0.6	0
533	Adrenal Gland. , 2022, , 461-486.		0
534	Cystic Lesions of the Pituitary: Clinicopathological Features Distinguishing Craniopharyngioma, Rathkeâ€™s Cleft Cyst, and Arachnoid Cyst. Obstetrical and Gynecological Survey, 2000, 55, 221-223.	0.2	0
535	FISHing in the thyroid: new gene rearrangements and new ideas about their pathophysiologic basis. Advances in Anatomic Pathology, 2001, 8, 359-360.	2.4	0
536	Creation of a Retrospective Searchable Neuropathologic Database from Print Archives: The UHN Experience. FASEB Journal, 2007, 21, A400.	0.2	0
537	Adenohypophysitis in rat pituitary allografts.. FASEB Journal, 2008, 22, .	0.2	0
538	Endocrine-Immune Interactions in Pituitary Pathology. , 1994, , 243-252.		0
539	Papillary Carcinoma of the Thyroid with Stromal Lymphoid Infiltrate. American Journal of Surgical Pathology, 1997, 21, 738-739.	2.1	0
540	A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.. Journal of Clinical Oncology, 2014, 32, e15621-e15621.	0.8	0

#	Article	IF	Citations
541	Pathology of Tumors of the Thyroid Gland. , 0, , 459-459.		0
542	Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. AACE Clinical Case Reports, 2018, 4, e289-e293.	0.4	0
543	SUN-453 Absence of Crooke's Hyaline Changes May Predict Worse Outcomes in Patients with Cushing Disease. Journal of the Endocrine Society, 2019, 3, .	0.1	0
544	Acidophil Stem Cell Tumor, Pituitary. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
545	Gonadotroph Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
546	Parathyroid Hyperplasia. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
547	Corticotroph Tumour. Encyclopedia of Pathology, 2020, , 1-6.	0.0	0
548	Pituitary Carcinoma. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
549	Null Cell Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
550	Mammosomatotroph Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
551	GATA2. Encyclopedia of Pathology, 2020, , 1-2.	0.0	0
552	Parathyroid Adenoma. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
553	C-Cell Hyperplasia. Encyclopedia of Pathology, 2020, , 1-4.	0.0	0
554	Lactotroph Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
555	Pituitary Neuroendocrine Tumor. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
556	Medullary Thyroid Carcinoma. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
557	Pancreatic Neuroendocrine Neoplasms. , 2021, , 245-261.		0
558	Parathyroid Neuroendocrine Neoplasms. , 2021, , 137-150.		0

#	Article	IF	Citations
559	Molecular profiling confirms historical immunohistochemistry in acromegaly. Endocrine-Related Cancer, 2020, 27, L1-L2.	1.6	0
560	Oncologic Outcome Prediction in Differentiated Thyroid Carcinoma: Assumption or Improved Accuracy?. Thyroid, 0, , .	2.4	0